U.S. Veterinary Orthopedic Medicine Market Size, Share & Trends Analysis Report By Product (Biologics, Viscosupplements, Pharmaceuticals), By Animal Type, By Application, By Route Of Administration, By End-use, And Segment Forecasts, 2024 - 2030

U.S. Veterinary Orthopedic Medicine Market Size, Share & Trends Analysis Report By Product (Biologics, Viscosupplements, Pharmaceuticals), By Animal Type, By Application, By Route Of Administration, By End-use, And Segment Forecasts, 2024 - 2030


U.S. Veterinary Orthopedic Medicine Market Growth & Trends

The U.S. veterinary orthopedic medicine market size is expected to reach USD 814.51 million by 2030, registering a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing pet population, adoption of pet insurance, rising prevalence of diseases among animals, and advancements in veterinary medicine.

For instance, in October 2023, the FDA approved Librela (bedinvetmab injection), making it the first monoclonal antibody for treating osteoarthritis-related pain in dogs. In addition, in April 2022, American Regent Animal Health, a division of American Regent, Inc., received FDA approval to extend the shelf life of Adequan Canine and Adequan i.m. The expiration date for both products was increased from 24 months to 36 months from the date of manufacture.

Key players in the veterinary orthopedic medicine market are engaging in strategic initiatives like product launches, collaborations, and acquisitions to make their market presence more prominent, impelling market growth. In September 2022, Zoetis acquired Jurox, a private animal health company specializing in veterinary medicines for livestock and companion animals. The deal, finalized in August 2021, included Jurox's operations in Australia and regional offices in the U.S., Canada, and the UK. Such initiatives are anticipated to drive market growth.

For instance, in October 2023, Athersys, Inc. (ATHX), a cell therapy and regenerative medicine company, entered into a licensing agreement with Ardent Animal Health. With this move, Athersys, known for its work with MultiStem (invimestrocel) in critical care, entered the field of animal health. This collaboration with Ardent, a veterinary biotech firm specializing in regenerative medicine and cancer therapies for animals, highlights Athersys’ commitment to advancing veterinary care.

Some key impacts of the pandemic and respective lockdowns on the market include dampened growth, decreased sales, supply chain disruptions, and operational challenges. However, the pandemic also propelled concerns over animal health and welfare, strengthened the pet parent and animal bond, and increased pet adoption. Moreover, the market witnessed an improved medicalization rate, pet expenditure, and adoption of pet insurance.

Increasing pet humanization and improved diagnostic rates were other positive impacts of the COVID-19 pandemic on the veterinary sector. In 2021, the market recorded increased demand and sale of veterinary medicines, including orthopedic medicines. In 2022, other macroeconomic uncertainties, such as global recession and cost inflation, adversely impacted the business. However, as the underlying market drivers remain unchanged owing to an increasing prevalence of orthopedic disorders in dogs and horses, the market is estimated to grow notably over the forecast period.

U.S. Veterinary Orthopedic Medicine Market Report Highlights
  • Based on product, pharmaceuticals segment dominated the market, accounting for a share of 46.72% in 2023. Pharmaceutical treatments for orthopedic diseases in pets, such as Non-steroidal Anti-inflammatory Drugs (NSAIDs) and pain relievers, have been widely used and established as effective treatments for managing pain and inflammation. On the other hand, the viscosupplements segment is anticipated to grow at the fastest CAGR of 8.23% during the forecast period
  • Based on animal type, the market is segmented into dogs and horses. The dogs segment dominated the market, accounting for a share of 51.98% in 2023. It is also anticipated to grow at the fastest CAGR of 7.80% in the coming decade
  • Based on application, the osteoarthritis segment accounted for the largest share of 60.65% of the market in 2023. The other segment is expected to grow at the fastest CAGR of 9.39% over the forecast period
  • Based on route of administration, the market is segmented into injectable, oral, and others (e.g., topical). The injectable segment dominated the market, accounting for a share of 60.40% in 2023. The others (e.g., topical) segment is anticipated to grow at the fastest CAGR of 8.22% in the coming decade
  • On the basis of end-use, veterinary clinics & hospitals segment accounted for the largest share of 53.59% of the market in 2023. The other segment is expected to grow at the fastest CAGR of 8.68% over the forecast period
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1 Methodology and Scope
1.1 Market Segmentation And Scope
1.1.1 Regional Scope
1.1.2 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information/data Analysis
1.4.1 Information Analysis
1.5 Market Formulation & Visualization
1.6 Data Validation & Publishing
1.7 Model Details
1.7.1 Approach 1: Commodity Flow Analysis
1.7.1.1 Hybrid Market Estimation Model
1.7.2 Global Market: Cagr Calculation
1.7.3 Approach 2: Parent Market Analysis
1.8 List Of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Segment Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 U.S. Veterinary Orthopedic Medicine Market Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Analysis
3.2 U.S. Veterinary Orthopedic Medicine Market Dynamics
3.3 Market Driver Impact Analysis
3.3.1 Increasing Incidence Of Orthopedic Problems
3.3.2 Growing Uptake Of Pet Insurance
3.3.3 Increase In Canine & Equine Population
3.3.4 Advancements In Veterinary Orthopedic Medicine
3.3.5 Supportive Initiatives
3.4 Market Restraint Impact Analysis
3.4.1. High Cost Of Treatment
3.5 Market Opportunity Analysis
3.6 Market Challenge Analysis
3.7 U.S. Veterinary Orthopedic Medicine Market: Porter’s 5 Forces Analysis
3.7.1 Bargaining Power Of Buyers: High
3.7.2 Bargaining Power Of Suppliers: Moderate - Low
3.7.3 Threat Of New Entrants: High
3.7.4 Threat Of Substitutes: Low - Moderate
3.7.5 Competitive Rivalry: High
3.8 U.S. Veterinary Orthopedic Medicine Market: Pestel Analysis
3.8.1 Political
3.8.2 Economic
3.8.3 Social
3.8.4 Technological
3.8.5 Environmental
3.8.6 Legal
3.9 Pet Owner Demographics & Behavior Analysis
3.10 Impact Of Covid-19 Pandemic, Recession & Inflation
3.11 U.S. Estimated Pet Dog & Horse Population (Million), 2018 To 2030
3.12 Estimated Number Of Intra-articularly Injected Canine Joints, 2022
Chapter 4 Product Estimates & Trend Analysis, 2018 - 2030 (USD Million)
4.1 U.S. Veterinary Orthopedic Medicine Market By Product: Key Takeaways
4.2 Product Movement Analysis & Market Share, 2022 & 2030
4.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecast, By Product (USD Million)
4.3.1 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Biologics (USD Million)
4.3.2 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Pharmaceuticals (USD Million)
4.4 Biologics
4.4.1 Biologics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.2 Stem Cells
4.4.2.1 Stem Cells Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.3 Platelet-rich Plasma (Prp)
4.4.3.1 Platelet-rich Plasma (Prp) Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.4 Other Biologics
4.4.4.1 Other Biologics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5 Viscosupplements
4.5.1 Viscosupplements Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.6 Pharmaceuticals
4.6.1 Pharmaceuticals Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.6.2 Steroids
4.6.2.1 Steroids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.6.3 Nsaids
4.6.3.1 Nsaids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.6.4 Others
4.6.4.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 5 Application Estimates & Trend Analysis, 2018 - 2030 (USD Million)
5.1 U.S. Veterinary Orthopedic Medicine Market By Solutions: Key Takeaways
5.2 Application Movement Analysis & Market Share, 2022 & 2030
5.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecast, By Application (USD Million)
5.4 Osteoarthritis (Oa)
5.4.1 Osteoarthritis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4.2 Degenerative Joint Disease
5.4.2.1 Degenerative Joint Disease Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4.3 Others
5.4.3.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 6 Route Of Administration Estimates & Trend Analysis, 2018 - 2030 (USD Million)
6.1 U.S. Veterinary Orthopedic Medicine Market By Route Of Administration: Key Takeaways
6.2 Route Of Administration Movement Analysis & Market Share, 2022 & 2030
6.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecast, By Route Of Administration (USD Million)
6.3.1 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Injectable (USD Million)
6.4 Injectable
6.4.1 Injectable Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.2 Intra-muscular
6.4.3 Intra-muscular Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.4 Intra-articular
6.4.5 Intra-articular Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.6 Others
6.4.7 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5 Oral
6.5.1 Oral Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.6 Others
6.6.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 7 Animal Type Estimates & Trend Analysis, 2018 - 2030 (USD Million)
7.1 U.S. Veterinary Orthopedic Medicine Market, By Animal Type: Key Takeaways
7.2 Dogs Movement Analysis & Market Share, 2022 & 2030
7.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Animal Type (USD Million)
7.3.1 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Dogs (USD Million)
7.4 Dogs
7.4.1 Dogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.2 Small Breeds
7.4.2.1 Small Breeds Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.3 Medium-sized Breeds
7.4.3.1 Medium-sized Breeds Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.4 Large Breeds
7.4.4.1 Large Breeds Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5 Horses
7.5.1 Horses Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 8 End-use Estimates & Trend Analysis, 2018 - 2030 (USD Million)
8.1 U.S. Veterinary Orthopedic Medicine Market By End-use: Key Takeaways
8.2 End-use Movement Analysis & Market Share, 2022 & 2030
8.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts By End-use (USD Million)
8.4 Veterinary Hospitals & Clinics
8.4.1 Veterinary Hospitals & Clinics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5 At-home
8.5.1 At-home Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6 Others
8.6.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Market Participant Categorization
9.2. Company Market Position Analysis/ Heap Map Analysis
9.3. Strategy Mapping
9.3.1. Mergers & Acquisitions
9.3.2. Partnerships & Collaborations
9.3.3. Others
9.4. Company Profiles
9.4.1. Zoetis
9.4.1.1. Participant’s Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. Ardent Animal Health, LLC
9.4.2.1. Participant’s Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. Enso Discoveries
9.4.3.1. Participant’s Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. Arthrex, Inc.
9.4.4.1. Participant’s Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. VetStem, Inc.
9.4.5.1. Participant’s Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Contura Vet US
9.4.6.1. Participant’s Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. MEDREGO LLC
9.4.7.1. Participant’s Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. PetVivo Holdings, Inc. (Spryng)
9.4.8.1. Participant’s Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. T-Cyte Therepeutics
9.4.9.1. Participant’s Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives
9.4.10. Boehringer Ingelheim Animal Health USA Inc.
9.4.10.1. Participant’s Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Benchmarking
9.4.10.4. Strategic Initiatives
9.4.11. American Regent, Inc.
9.4.11.1. Participant’s Overview
9.4.11.2. Financial Performance
9.4.11.3. Product Benchmarking
9.4.11.4. Strategic Initiatives
9.4.12. Bimeda U.S.
9.4.12.1. Participant’s Overview
9.4.12.2. Financial Performance
9.4.12.3. Product Benchmarking
9.4.12.4. Strategic Initiatives
9.4.13. Nucleus ProVets
9.4.13.1. Participant’s Overview
9.4.13.2. Financial Performance
9.4.13.3. Product Benchmarking
9.4.13.4. Strategic Initiatives
Chapter 10. Key Takeaways

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings